Edwards Lifesciences’ (EW) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a research report released on Wednesday morning,Benzinga reports. BTIG Research currently has a $103.00 target price on the medical research company’s stock.

Several other brokerages have also recently issued reports on EW. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $100.00 price target (up previously from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research report on Monday, January 12th. Finally, National Bank Financial set a $92.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $79.29 on Wednesday. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a market cap of $46.01 billion, a PE ratio of 43.33, a P/E/G ratio of 2.98 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The business has a 50-day simple moving average of $83.73 and a two-hundred day simple moving average of $81.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the business earned $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 43,804 shares of company stock valued at $3,699,082. Insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after buying an additional 365,581 shares during the period. Wellington Management Group LLP grew its position in Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after acquiring an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Jennison Associates LLC increased its stake in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after purchasing an additional 45,555 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Management raised its 2026 profit outlook and signaled robust demand for heart‑valve devices, reassuring investors about medium‑term growth prospects. This beat street hopes and helped lift the stock. Edwards Lifesciences forecasts 2026 profit above estimates on heart devices strength
• Positive Sentiment: Q4 revenue grew ~13% YoY, led by TAVR and a >40% jump in TMTT sales — evidence that core product momentum remains intact and supports the company’s sales guidance for 2026. Edwards Lifesciences Reports Fourth Quarter Results
• Positive Sentiment: Company updated Q1 2026 EPS guidance (0.700–0.760) above consensus, which reduces near‑term uncertainty and supports analyst bullishness. Edwards Lifesciences Reports Fourth Quarter Results
• Positive Sentiment: Multiple firms reiterated Buy/Overweight ratings and lifted price targets (Wells Fargo to $100, BTIG and others at ~$103), signaling strong analyst conviction and providing additional upside narrative. Benzinga
• Neutral Sentiment: Analysts and strategy writers flagged an options/contrarian trade idea following the earnings release — useful to traders but not a direct fundamental catalyst. Options Corner: Edwards Lifesciences Poor Start To The New Year Offers A Contrarian Opportunity
• Neutral Sentiment: Company earnings call and transcripts provide detail on execution and product cadence; useful for positioning but largely reiterative of management’s growth message. Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS missed consensus (adjusted $0.58 vs. ~$0.62), and some reports show sizable pressure on GAAP profitability and operating income — a reminder margins are under near‑term strain despite revenue growth. EW’s Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
• Negative Sentiment: Some data vendors highlighted sharp declines in GAAP net income and notable insider selling activity; both items can weigh on sentiment if investors focus on near‑term cash/profit trends rather than adjusted metrics. Edwards Lifesciences (EW) Stock Falls on Q4 2025 Earnings

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.